Norfolk, VA, October 12, 2023 – ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company focused on harnessing the...
Read MoreReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071 in Hospitalized Patients with Steroid-Refractory Acute Graft-Versus-Host Disease...
Read MoreNorfolk, VA, September 5, 2023 – ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company addressing life-threatening rare diseases...
Read MoreNORFOLK, Va., August 1, 2023 — ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company dedicated to addressing life-threatening...
Read MoreNorfolk, VA, June 27, 2023 – ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening rare diseases through harnessing the...
Read MoreNorfolk, VA, June 1, 2023 – ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening rare diseases through harnessing the...
Read MorePresenting proof-of-mechanism clinical trial data in healthy volunteers of RLS-0071, the Company’s dual action complement inhibitor and innate anti-inflammatory product...
Read MoreRLS-0071 is ReAlta’s lead dual-action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic ischemic encephalopathy,...
Read MoreNorfolk, VA, June 1st, 2022 – ReAlta Life Sciences, Inc. (“ReAlta”) a clinical stage, rare disease company addressing life-threatening diseases...
Read More